EGFR and head and neck squamous cell carcinoma: To date, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab and programmed death receptor-1 (PD-1) antibodies nivolumab and pembrolizumab are approved as targeted agents for the treatment of HNSCC.